Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119132 | 0.91 | CA1 (0.58) | ACP3CA4ALDH1A1CA12CA1 | |
| SCHEMBL9160904 | 0.87 | ACP3 (0.56) | ACP3CA4LTA4HALDH1A1PBRM1 | |
| SCHEMBL7593429 | 0.83 | ACP3 (0.61) | ACP3CA4LTA4HALDH1A1PBRM1 | |
| SCHEMBL5941221 | 0.82 | PBRM1 (0.62) | ACP3CA4LTA4HALDH1A1PBRM1 | |
| SCHEMBL8429413 | 0.82 | PBRM1 (0.62) | ACP3CA4LTA4HALDH1A1PBRM1 | |
| SCHEMBL13295540 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1PBRM1 | |
| SCHEMBL40557 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1PBRM1 | |
| SCHEMBL13295537 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1PBRM1 | |
| SCHEMBL14205685 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1PBRM1 | |
| SCHEMBL34971 | 0.82 | SLC2A1 (0.61) | ACP3CA4LTA4HALDH1A1PBRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183966-B2 | Solid phase peptide synthesis via side chain attachment | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2019-01-22 | — | — | US | disclosed |
| EP-2440572-B1 | LACTAM-BRIDGED MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160362445-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-12-15 | — | — | US | disclosed |
| US-9388212-B2 | Solid phase peptide synthesis via side chain attachment | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2016-07-12 | — | — | US | disclosed |
| US-9273098-B2 | Lactam-bridged melanocortin receptor-specific peptides | PALATIN TECHNOLOGIES, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140235789-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2014-08-21 | — | — | US | disclosed |
| WO-2013098802-A2 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2013-07-04 | — | — | WO | disclosed |
| EP-2440572-A2 | LACTAM-BRIDGED MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | Palatin Technologies, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120077957-A1 | Lactam-Bridged Melanocortin Receptor-Specific Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010144341-A2 | LACTAM-BRIDGED MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2010-12-16 | — | — | WO | disclosed |
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-1062205-A2 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
| WO-1999043654-A2 | INHIBITORS OF PHOSPHOLIPASE ENZYMES | GENETICS INSTITUTE, INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0929534-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013356-A1 | TRYCYCLIC COMPOUNDS AS PROSTAGLANDIN I2 RECEPTOR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077957-A1 | Lactam-Bridged Melanocortin Receptor-Specific Peptides | MC1R, MC3R, MC4R | ACP3 1797/4885CA4 4787/4885LTA4H 3192/4885 |
| US-20160362445-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | HDGF, VIP, HDGFL3 | ACP3 2233/4885CA4 4366/4885LTA4H 2103/4885 |
| US-20140235789-A1 | SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT | HDGF, VIP, HDGFL3 | ACP3 2233/4885CA4 4366/4885LTA4H 2103/4885 |
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | ACP3 4506/4885CA4 2498/4885LTA4H 492/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | ACP3 3108/4885CA4 1589/4885LTA4H 2942/4885 |
| US-10183966-B2 | Solid phase peptide synthesis via side chain attachment | HDGF, VIP, HDGFL3 | ACP3 2233/4885CA4 4366/4885LTA4H 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.